Novavax
53
0
1
48
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
7.5%
4 terminated/withdrawn out of 53 trials
92.3%
+5.8% vs industry average
30%
16 trials in Phase 3/4
25%
12 of 48 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (53)
A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine
Role: lead
Safety and Immunogenicity of NVX-CoV2705
Role: collaborator
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
Role: lead
Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years
Role: lead
Efficacy and Safety of NVX-CoV2705
Role: lead
Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
Role: lead
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
Role: collaborator
Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations
Role: collaborator
A Strain Change Study for SARS-CoV-2 rS Vaccines
Role: lead
Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines
Role: lead
Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
Role: lead
A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom
Role: lead
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
Role: lead
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
Role: lead
Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine
Role: lead
Lot Consistency Study of COVID-19 and Influenza Combination Vaccine
Role: lead
Safety and Efficacy of R0.6C Vaccine
Role: collaborator
Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines
Role: lead
A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine
Role: lead
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
Role: lead